Some therapeutic approaches targeting IL-6 are available, such as tocilizumab (TCZ), the first IL-6-targeted biologic approved for the treatment of various inflammatory diseases (including rheumatoid arthritis and systemic arthritis). The gene discussed is IL6; the disease is rheumatoid arthritis.